Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

A Study Being Conducted at Multiple Locations to Compare Safety and Efficacy of Three Different Regimens; (1) High-Dose Lenalidomide; (2) Lenalidomide + Azacitidine; or (3) Azacitidine in Subjects ≥ 65 Years With Newly-Diagnosed Acute Myeloid Leukemia

ClinicalTrials.gov ID: NCT01358734

Public ClinicalTrials.gov record NCT01358734. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 16, 2026, 7:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Multicenter, Randomized, Open-label, Parallel-group Study of a Lenalidomide (Revlimid®) Regimen or a Sequential Azacitidine (Vidaza®) Plus Lenalidomide (Revlimid®) Regimen Versus an Azacitidine (Vidaza®) Regimen for Therapy of Older Subjects With Newly Diagnosed Acute Myeloid Leukemia

Study identification

NCT ID
NCT01358734
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Celgene
Industry
Enrollment
88 participants

Conditions and interventions

Interventions

  • Azacitidine Drug
  • Best Supportive Care (BSC) Other
  • Lenalidomide Drug

Drug · Other

Eligibility (public fields only)

Age range
65 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 26, 2012
Primary completion
May 18, 2015
Completion
May 14, 2018
Last update posted
Jun 24, 2019

2012 – 2018

United States locations

U.S. sites
24
U.S. states
18
U.S. cities
24
Facility City State ZIP Site status
(210) University of Arizona Cancer Center Tucson Arizona 85724
(180) University of California, San Diego La Jolla California 92093-0960
(240) Cedars-Sinai Medical Center Los Angeles California 90048
(215) Hematology Oncology Medical Group Orange California 92868
(130) UC Davis Medical Center Sacramento California 95857
(200) Coastal Integrative Cancer Care San Luis Obispo California 93401
(125) University of Stanford Stanford California 94305
(115) University of Colorado Anschultz Cancer Center Aurora Colorado 80045
(145) Mount Sinai Comprehensive Cancer Center Miami Beach Florida 33140
(140) Rush University Medical Center Chicago Illinois 60612
(185) The University of Kansas Cancer Center Westwood Kansas 66205
(175) University Lousiville Louisville Kentucky 40202
(195) Tulane University Hospital Tulane Cancer Center New Orleans Louisiana 70072
(235) University of Minnesota Minneapolis Minnesota 55455
(100) Washington University School of Medicine St Louis Missouri 63110-1093
(150) Billings Clinic Billings Montana 59101
(165) Mount Sinai Medical Center New York New York New York 10029-65749
(160) The Western Pennsylvania Hospital- Cancer Institute Pittsburgh Pennsylvania 15224-1791
(205) Greenville Hospital System Greenville South Carolina 29605
(120) Avera Cancer Institute Sioux Falls South Dakota 57105
(230) Tennessee Oncology, PLLC Nashville Tennessee 37203
(105) University of Texas Southwestern Medical Center Simmons Comprehensive Cancer Center Dallas Texas 75390-9179
(155) Cancer Care Centers of South Texas San Antonio Texas 78229
(135) University of Wisconsin Madison Wisconsin 53792

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01358734, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 24, 2019 · Synced May 16, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01358734 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →